

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
26 April 2007 (26.04.2007)

PCT

(10) International Publication Number
WO 2007/047609 A3

(51) International Patent Classification:

A61K 38/17 (2006.01) A61K 39/395 (2006.01)
A61K 48/00 (2006.01) C07H 21/02 (2006.01)

(21) International Application Number:

PCT/US2006/040431

(22) International Filing Date: 16 October 2006 (16.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/728,292 19 October 2005 (19.10.2005) US

(71) Applicants (for all designated States except US):
CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY [US/US]; 300 American Road, Morris Plains, New Jersey 07950 (US). **IMMUNOMEDICS, INC.** [US/US]; 300 American Road, Morris Plains, New Jersey 07950 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GOLDENBERG, David M.** [US/US]; 300 American Plains, Morris Plains, New Jersey 07950 (US). **CHANG, Chien Hsing** [US/US]; 300 American Road, Morris Plains, New Jersey 07950 (US).

(74) Agents: **NAKASHIMA, Richard A.** et al.; **FAEGRE & BENSON LLP**, Customer No. 35657, 3200 Wells Fargo Center, 1700 Lincoln Street, Denver, Colorado 80203-4532 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

[Continued on next page]

(54) Title: INHIBITION OF PLACENTA GROWTH FACTOR (PIGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS

Figure 1



(57) Abstract: The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PIGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PIGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PIGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PIGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PIGF expression levels may be determined by any known method to select those patients most likely to respond to PIGF targeted therapies.

WO 2007/047609 A3



— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) **Date of publication of the international search report:**
19 March 2009